Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04942054 · ClinicalTrials.gov registry record · Phase 1
A Study in Patients With Advanced Breast Cancer
A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04942054 is a Phase 1 study that was terminated before completion, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 9 participants.
The verdict
NCT04942054, a Phase 1 study, was terminated before completion, sponsored by Sun Pharma Advanced Research Company Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or with out ESR1 mutation.
Interventions
- DRUG Part 1
- DRUG Part 2
- DRUG Part 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-05-20 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04942054
The ClinicalTrials.gov registry entry for NCT04942054 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Part 1 is the first listed.
NCT04942054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04942054 about?
NCT04942054 is a clinical study titled "A Study in Patients With Advanced Breast Cancer". A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisat...
What is the current status of trial NCT04942054?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-05-20. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04942054?
The interventions under investigation include: Part 1 (DRUG), Part 2 (DRUG), Part 3 (DRUG).
Who is sponsoring clinical trial NCT04942054?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.